Loading patent…
AssigneeGenomatica, Inc.
InventorsAnthony P. BURGARD, Robin E. OSTERHOUT, Priti PHARKYA, Mark J. BURK
Estimating the term…
The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.
The non-naturally occurring microbial organism of claim 1, wherein said microbial organism comprises three, four, five, six or seven exogenous nucleic acids each encoding a caprolactone pathway enzyme.
The non-naturally occurring microbial organism of claim 1, wherein said at least one exogenous nucleic acid is a heterologous nucleic acid.
The non-naturally occurring microbial organism of claim 1, wherein said non-naturally occurring microbial organism is in a substantially anaerobic culture medium.
The non-naturally occurring microbial organism of claim 1, further comprising:
A method for producing caprolactone, comprising culturing the non-naturally occurring microbial organism of claim 1 under conditions and for a sufficient period of time to produce caprolactone.
Culture medium comprising bioderived caprolactone, wherein said bioderived caprolactone has a carbon-12, carbon-13 and carbon-14 isotope ratio that reflects an atmospheric carbon dioxide uptake source.
Bioderived caprolactone having a carbon-12, carbon-13 and carbon-14 isotope ratio that reflects an atmospheric carbon dioxide uptake source.
(canceled)
-17. (canceled)
(canceled)
(canceled)
-25. (canceled)
Dependencies are inferred from the claim text.